Somatostatin receptor expression in thyroid disease
- 14 May 2013
- journal article
- research article
- Published by Wiley in International Journal of Experimental Pathology
- Vol. 94 (3) , 226-229
Abstract
Summary: Somatostatin analogues are commercially available and used for the management of acromegaly and neuroendocrine tumours, but the expression of the receptors as a target in thyroid disease has not been explored. To assess somatostatin (SST) and somatostatin receptor (SSTR1‐5) expression in both normal and thyroid disorders, as a potential target for somatostatin analogue therapy, 67 thyroid tissue specimens were reviewed: 12 differentiated thyroid carcinomas, 14 follicular adenomas, 17 multinodular goitres, 14 Graves disease, 10 Hashimotos thyroiditis specimens and five normal thyroids. Tissue was immunostained for SST and SSTR1‐5. Positivity and the degree of positivity were recorded by double‐blinded observers. Somatostatin receptor expression was highly expressed in normal tissue for SSTR1, 3, 4 and 5 (5 of 5, 4 of 5, 4 of 5 and 5 of 5 respectively) whilst SST and SSTR 2a and b were not expressed at all. The commonest receptor expressed for all pathological subtypes grouped together was SSTR2b (63 specimens). The commonest receptors expressed in differentiated thyroid cancer were SSTR5 (11 of 12 specimens) and SSTR2b (10 of 12 specimens). The commonest receptor expressed in benign disease was SSTR2b (53 of 55 specimens). SSTR5 was significantly under‐expressed in Graves disease (P < 0.05). This study illustrates that SSTR 1, 3, 4 and 5 are highly expressed in normal, benign and malignant thyroid tissue. SSTR 2a and 2b appear absent in normal tissue and present in benign and malignant thyroid tissue (P < 0.02). This suggests that focussed SSTR2 treatment may be a potential therapeutic target.Keywords
This publication has 25 references indexed in Scilit:
- Somatostatin Receptor Subtype Expression in Human Thyroid TumoursHormone and Metabolic Research, 2010
- Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigationThyroid Research, 2009
- Antitumor effects of somatostatinMolecular and Cellular Endocrinology, 2008
- Modulation of expression of somatostatin receptor subtypes in Graves’ ophthalmopathy orbits: relevance to novel analogsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Gammagrafía con octreótido en la orbitopatía distiroideaArchivos de la Sociedad Española de Oftalmología, 2007
- Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumoursActa Oncologica, 2007
- Somatostatin ReceptorsDigestion, 2000
- Uptake of In-111 Pentetreotide by Normally Functioning Nodular GoitersClinical Nuclear Medicine, 1997
- Somatostatin Receptor Subtype Expression in Human Thyroid and Thyroid Carcinoma Cell LinesThe Journal of Clinical Endocrinology & Metabolism, 1997
- Somatostatin receptor activation of cellular effector systemsCellular Signalling, 1995